271 related articles for article (PubMed ID: 28195363)
1. Liver fibrosis scores predict liver disease mortality in the United States population.
Unalp-Arida A; Ruhl CE
Hepatology; 2017 Jul; 66(1):84-95. PubMed ID: 28195363
[TBL] [Abstract][Full Text] [Related]
2. Liver fat scores predict liver disease mortality in the United States population.
Unalp-Arida A; Ruhl CE
Aliment Pharmacol Ther; 2018 Nov; 48(9):1003-1016. PubMed ID: 30295948
[TBL] [Abstract][Full Text] [Related]
3. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
Kim D; Kim WR; Kim HJ; Therneau TM
Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
[TBL] [Abstract][Full Text] [Related]
5. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
Unalp-Arida A; Ruhl CE
Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
[TBL] [Abstract][Full Text] [Related]
6. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.
Unalp-Arida A; Ruhl CE
Hepatology; 2016 Apr; 63(4):1170-83. PubMed ID: 26663021
[TBL] [Abstract][Full Text] [Related]
8. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
10. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
Bhala N; Angulo P; van der Poorten D; Lee E; Hui JM; Saracco G; Adams LA; Charatcharoenwitthaya P; Topping JH; Bugianesi E; Day CP; George J
Hepatology; 2011 Oct; 54(4):1208-16. PubMed ID: 21688282
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
14. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study.
Choi SW; Kweon SS; Lee YH; Ryu SY; Nam HS; Shin MH
PLoS One; 2022; 17(12):e0277729. PubMed ID: 36512564
[TBL] [Abstract][Full Text] [Related]
15. Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk.
Delgado GE; Kleber ME; Moissl AP; Yazdani B; Kusnik A; Ebert MP; März W; Krämer BK; Lammert A; Teufel A
Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(4):G252-G261. PubMed ID: 34132110
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.
Marella HK; Reddy YK; Jiang Y; Ganguli S; Podila PSB; Snell PD; Kovalic AJ; Cholankeril G; Singal AK; Nair S; Maliakkal B; Satapathy SK
Clin Transl Gastroenterol; 2020 Apr; 11(4):e00165. PubMed ID: 32352687
[TBL] [Abstract][Full Text] [Related]
17. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease.
Chen Q; Li Q; Li D; Chen X; Liu Z; Hu G; Wang J; Ling W
Atherosclerosis; 2020 Apr; 299():45-52. PubMed ID: 32240838
[TBL] [Abstract][Full Text] [Related]
18. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
[TBL] [Abstract][Full Text] [Related]
19. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
